Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
Johns Hopkins University Lays Off 110 Employees as Federal Research Funding Declines 
Kioxia Targets U.S. Listing as AI Chip Boom Accelerates 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Alibaba Shares Fall After Anthropic Alleges Massive AI Model Distillation Campaign 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
Bayer Wins Major U.S. Supreme Court Roundup Lawsuit, Shares Surge 
SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
SOUTH SAN FRANCISCO, Calif., Feb. 29, 2016 -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific innovation, today announced that Isaac Ciechanover, M.D., the Company’s President and Chief Executive Officer, will present at the Cowen and Company 36th Annual Health Care Conference on Monday, March 7, 2016 at 3:20 p.m. ET. The conference will be held at the Boston Marriott Copley Place Hotel in Boston, MA.
A live webcast of the presentation will be available by visiting the Investors section of the Atara Bio website at www.atarabio.com. An archived replay of the webcast will be available on the Company's website for 14 days following the presentation.
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. is a biopharmaceutical company developing meaningful therapies for patients with unmet medical needs in diseases that have seen limited therapeutic innovation, with an initial focus on immunotherapy and oncology. Atara Bio's programs include T-cell product candidates and molecularly targeted product candidates. The T-cell product candidates include EBV-CTL, CMV-CTL and WT1-CTL and harness the power of the immune system to recognize and attack cancer cells and cells infected with certain viruses. The molecularly targeted product candidates include STM 434. These product candidates target activin and myostatin, members of the TGF-beta family of proteins, and have demonstrated the potential to have therapeutic benefit in a number of clinical indications.
INVESTOR & MEDIA CONTACT: Investors: Steve Klass 212-213-0006 x331 [email protected] Media: Justin Jackson 212-213-0006 x327 [email protected]
